CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioPharma Dive
Original article

A new immuno-oncology play raises $225M for a next-generation drug

Positive
AI Analysis

Summary

Solstice Oncology raised $225M for a next-generation immuno-oncology drug from Harbour BioMed targeting CTLA-4, aimed at addressing weaknesses in existing therapies in this class.

Importance:6/10
Sentiment:
0.60
immuno-oncologyCTLA-4fundingcancer immunotherapynext-generation drug

Read the original article

Published by BioPharma Dive on September 9, 2026 11:00 AM

Read Original